Chunxia Qin1,2, Fuqiang Shao1,2, Yongkang Gai1,2, Qingyao Liu1,2, Weiwei Ruan1,2, Fang Liu1,2, Fan Hu1,2, Xiaoli Lan3,2. 1. Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; and. 2. Hubei Key Laboratory of Molecular Imaging, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. 3. Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; and xiaoli_lan@hust.edu.cn.
Abstract
We sought to evaluate the performance of 68Ga-DOTA-FAPI-04 ( 68 Ga-FAPI) PET/MR for the diagnosis of primary tumor and metastatic lesions in patients with gastric carcinomas and to compare the results with those of 18F-FDG PET/CT. Methods: Twenty patients with histologically proven gastric carcinomas were recruited, and each patient underwent both 18F-FDG PET/CT and 68 Ga-FAPI PET/MR. A visual scoring system was established to compare the detectability of primary tumors and metastases in different organs or regions (the peritoneum, abdominal lymph nodes, supradiaphragmatic lymph nodes, liver, ovary, bone, and other tissues). The original SUVmax and normalized SUVmax (calculated by dividing a lesion's original SUVmax with the SUVmean of the descending aorta) of selected lesions on both 18F-FDG PET/CT and 68Ga-FAPI PET/MR were measured. Original/normalized SUVmax-FAPI and SUVmax-FDG were compared for patient-based (including a single lesion with the highest activity uptake in each organ/region) and lesion-based (including all lesions [≤5] or the 5 lesions with highest activity [>5]) analyses, respectively. Results: The 20 recruited patients (median age: 56.0 y; range: 29-70 y) included 9 men and 11 women, 14 patients for initial staging and 6 for recurrence detection. 68Ga-FAPI PET was superior to 18F-FDG PET for primary tumor detection (100.00% [14/14] vs. 71.43% [10/14]; P = 0.034), and the former had higher tracer uptake levels (P < 0.05). 68Ga-FAPI PET was superior to 18F-FDG PET in both patient-based and lesion-based evaluation except for the metastatic lesions in supradiaphragmatic lymph nodes and ovaries. Additionally, multiple sequences of MR images were beneficial for the interpretation of hepatic metastases in 3 patients, uterine and rectal metastases in 1 patient, ovarian lesions in 7 patients, and osseous metastases in 2 patients. Conclusion: 68Ga-FAPI PET/MR outperformed 18F-FDG PET/CT in visualizing the primary and most metastatic lesions of gastric cancer and might be a promising method, with the potential of replacing 18F-FDG PET/CT.
We sought to evaluate the performance of 68Ga-DOTA-FAPI-04 ( 68 Ga-FAPI) PET/MR for the diagnosis of primary tumor and metastatic lesions in patients with gastric carcinomas and to compare the results with those of 18F-FDG PET/CT. Methods: Twenty patients with histologically proven gastric carcinomas were recruited, and each patient underwent both 18F-FDG PET/CT and 68 Ga-FAPI PET/MR. A visual scoring system was established to compare the detectability of primary tumors and metastases in different organs or regions (the peritoneum, abdominal lymph nodes, supradiaphragmatic lymph nodes, liver, ovary, bone, and other tissues). The original SUVmax and normalized SUVmax (calculated by dividing a lesion's original SUVmax with the SUVmean of the descending aorta) of selected lesions on both 18F-FDG PET/CT and 68Ga-FAPI PET/MR were measured. Original/normalized SUVmax-FAPI and SUVmax-FDG were compared for patient-based (including a single lesion with the highest activity uptake in each organ/region) and lesion-based (including all lesions [≤5] or the 5 lesions with highest activity [>5]) analyses, respectively. Results: The 20 recruited patients (median age: 56.0 y; range: 29-70 y) included 9 men and 11 women, 14 patients for initial staging and 6 for recurrence detection. 68Ga-FAPI PET was superior to 18F-FDG PET for primary tumor detection (100.00% [14/14] vs. 71.43% [10/14]; P = 0.034), and the former had higher tracer uptake levels (P < 0.05). 68Ga-FAPI PET was superior to 18F-FDG PET in both patient-based and lesion-based evaluation except for the metastatic lesions in supradiaphragmatic lymph nodes and ovaries. Additionally, multiple sequences of MR images were beneficial for the interpretation of hepatic metastases in 3 patients, uterine and rectal metastases in 1 patient, ovarian lesions in 7 patients, and osseous metastases in 2 patients. Conclusion: 68Ga-FAPI PET/MR outperformed 18F-FDG PET/CT in visualizing the primary and most metastatic lesions of gastric cancer and might be a promising method, with the potential of replacing 18F-FDG PET/CT.
Authors: Hyeon Hwa Oh; Sang Eok Lee; In Seok Choi; Won Jun Choi; Dae Sung Yoon; Hyun Sik Min; Yu Mi Ra; Ju Ik Moon; Yun Hee Kang Journal: J Surg Oncol Date: 2011-05-25 Impact factor: 3.454
Authors: Clemens Kratochwil; Paul Flechsig; Thomas Lindner; Labidi Abderrahim; Annette Altmann; Walter Mier; Sebastian Adeberg; Hendrik Rathke; Manuel Röhrich; Hauke Winter; Peter K Plinkert; Frederik Marme; Matthias Lang; Hans-Ulrich Kauczor; Dirk Jäger; Jürgen Debus; Uwe Haberkorn; Frederik L Giesel Journal: J Nucl Med Date: 2019-04-06 Impact factor: 10.057
Authors: Baodong Liu; Miguel Ramalho; Mamdoh AlObaidy; Kiran K Busireddy; Ersan Altun; Janaka Kalubowila; Richard C Semelka Journal: World J Radiol Date: 2014-08-28
Authors: Elizabeth J Hamson; Fiona M Keane; Stefan Tholen; Oliver Schilling; Mark D Gorrell Journal: Proteomics Clin Appl Date: 2014-03-24 Impact factor: 3.494
Authors: Frederik L Giesel; Clemens Kratochwil; Thomas Lindner; Manfred M Marschalek; Anastasia Loktev; Wencke Lehnert; Jürgen Debus; Dirk Jäger; Paul Flechsig; Annette Altmann; Walter Mier; Uwe Haberkorn Journal: J Nucl Med Date: 2018-08-02 Impact factor: 10.057
Authors: E Novruzov; K Dendl; H Ndlovu; P L Choyke; M Dabir; M Beu; F Novruzov; E Mehdi; F Guliyev; S A Koerber; I Lawal; G Niegisch; J Debus; U Haberkorn; M Sathekge; F L Giesel Journal: Mol Imaging Biol Date: 2022-03-29 Impact factor: 3.484